Researchers have identified RND3, an atypical member of the Rho GTPase family, as a common downstream target suppressed by both the transcriptional and structural functions of β-catenin in hepatocellular carcinoma (HCC). This dual regulation offers new insight into how structural and transcriptional drivers promote liver tumorigenesis regardless of mutational status.
Beta-Catenin Represses RND3 Expression Through Multiple Pathways
Tumor development in the liver relies heavily on oncogenic mutations and physical cellular factors. β-Catenin acts as a primary driver bridging both mechanisms, yet its exact pathways for regulating downstream targets remained largely unknown until now.
The research differentiates between the protein’s operational modes. Wild-type β-catenin targets RND3 transcription by engaging the Hippo signaling pathway. Conversely, oncogenic variants of β-catenin suppress RND3 expression by deploying miR-512-3p directly to its 3’ untranslated region (3’UTR).
Intrahepatic Metastasis Correlates With Downregulated RND3
Previous scientific work established that RND3 levels drop significantly in human hepatocellular carcinoma, a downregulation that directly correlates with the spread of tumors within the liver. Until this recent study, however, the exact molecular triggers behind this dysregulation remained missing from the literature.
By connecting reduced RND3 levels to both structural adhesion changes and transcriptional programs driven by oncogenic β-catenin, the study isolates Rnd3 as a critical mediator of mechanosensitive responses. These cellular responses govern how cancer cells adhere to one another and migrate across tissue boundaries during metastasis.
What is RND3 and what role does it play in liver cancer?
What is RND3 and what role does it play in liver cancer?
RND3 is an atypical member of the Rho GTPase family whose expression is downregulated in hepatocellular carcinoma. It acts as a common target of β-catenin and mediates mechanosensitive responses linked to cell-to-cell adhesion and intrahepatic metastasis.
How does wild-type β-catenin differ from oncogenic β-catenin in regulating RND3?
Wild-type β-catenin suppresses RND3 transcription through the Hippo pathway. In contrast, oncogenic β-catenin downregulates RND3 expression by utilizing miR-512-3p to target its 3’UTR.
Related reading